Cytokinetics, Incorporated announced positive results from the MAPLE-HCM trial comparing aficamten to metoprolol in patients with hypertrophic cardiomyopathy. Aficamten demonstrated superiority to metoprolol in improving exercise capacity and symptoms in patients with obstructive HCM. The primary endpoint showed a statistically significant difference in peak oxygen uptake between the two treatments. Aficamten also outperformed metoprolol in five of six secondary endpoints, including improvements in functional class and symptom burden. The drug is currently under FDA review with a target action date of December 26, 2025. Adverse events were similar between the two groups, with one patient on aficamten passing away due to a viral illness. A summary of new data related to the clinical development of aficamten was presented at the European Society of Cardiology Congress 2025. The most common adverse event reported for aficamten was hypertension (10.2% of patients) compared to metoprolol. Investor webcast information is available for those interested in learning more about the primary results from MAPLE-HCM. Aficamten is an investigational drug being evaluated as a treatment for hypertrophic cardiomyopathy (HCM) in various clinical trials. HCM is a disease affecting the heart muscle, with potential complications such as reduced exercise capacity and cardiovascular issues. Cytokinetics is a biopharmaceutical company focused on developing new medicines for cardiac muscle dysfunction. Cytokinetics announced positive results from a Phase 2 clinical trial of aficamten, a potential treatment for obstructive hypertrophic cardiomyopathy. The study compared aficamten to metoprolol monotherapy and showed promising results in improving exercise capacity and quality of life for patients with this condition. This is significant news for the estimated 650,000 Americans living with hypertrophic cardiomyopathy, a genetic heart disease that can lead to heart failure and sudden cardiac death. The findings of this trial offer hope for a new treatment option in the future.

Read more at 1. “Tesla announces record quarterly profits, exceeding expectations” – GlobeNewswire
2. “CDC reports significant drop in COVID-19 cases nationwide” – GlobeNewswire
3. “Apple unveils latest iPhone model with improved camera capabilities” – GlobeNewswire
4. “Federal Reserve raises interest rates in response to surging inflation” – GlobeNewswire
5. “Amazon launches new delivery drone service in select cities” – GlobeNewswire: Cytokinetics Announces Primary Results from MAPLE-HCM